Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients.

about

Auscultatory versus oscillometric blood pressure measurement in patients with atrial fibrillation and arterial hypertension.Current Atrial Fibrillation Ablation: An Alert for the Prevention and Treatment of Esophageal Lesions.

P2860

Q36320870-32C9829B-D810-4F84-AC1D-15A674F4040A Q42601438-D64F8212-C10E-4569-A58B-F0835C700B49

P2860

Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients.

Item

http://www.wikidata.org/entity/Q43066406

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@en

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@nl

type

Item

label

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@en

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@nl

prefLabel

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@en

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@nl

P1476

Factors in Deciding between No ...... Atrial Fibrillation Patients.

@en

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

CHADS2 score in predicting cerebrovascular events: a meta-analysis

Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review

Dabigatran versus warfarin in patients with atrial fibrillation

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly

Apixaban in patients with atrial fibrillation.

Atrial fibrillation in decompensated heart failure: associated factors and in-hospital outcome.

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

P304

1-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.5935/ABC.20160010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Maurício Scanavacca

Francisco Darrieux

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26815647

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

4728588

http://www.w3.org/2001/XMLSchema#string

Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients.

about

P2860

P2860

Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932